Clinical Trials Directory

Trials / Terminated

TerminatedNCT01756326

Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures

A Pivotal Phase 2b/3, Multicentre, Randomised, Open, Controlled Study on the Efficacy and Safety of Autologous Osteoblastic Cells (PREOB®) Implantation in Non-Infected Hypotrophic Non-Union Fractures

Status
Terminated
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
5 (actual)
Sponsor
Bone Therapeutics S.A · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Fracture healing is a complex physiological process caused by interaction of cellular elements, cytokines and signaling proteins, which results in the formation of new bone (Gerstenfeld et al., 2003). Depending on fracture site, complexity, co-morbidities and other factors, 10% of all fractures will eventually fail to unite. Non-union fractures are defined as fractures that are at least six to nine months old and in which there have been no signs of healing for the last three months. Various causes have been evoked for impaired healing in hypotrophic (atrophic and oligotrophic) non-unions, including poor fracture stabilization, local infection and failure of the osteoblastic cells to multiply. Currently the treatment of choice for non-unions, particularly atrophic non-unions, is bone autograft (or allograft), combined or not with intramedullary nailing, plating, and external fixation devices (Kanakaris et al., 2007). This procedure produces good results but requires an invasive surgery of several hours under general anesthesia and a few days of hospitalization. Because of this, major complications have been reported in up to 20-30% of patients (Pieske et al., 2009, Zimmerman et al., 2009). This Phase 2b/3 study aims at demonstrating the safety and efficacy of PREOB®, a proprietary population of autologous osteoblastic cells, in the treatment of hypotrophic non-union fractures of long bones. PREOB® will be compared to Bone Autograft in a non-inferiority design.

Conditions

Interventions

TypeNameDescription
DRUGPREOB® Implantation
PROCEDUREBone Autograft

Timeline

Start date
2012-06-01
Primary completion
2018-04-01
Completion
2019-04-01
First posted
2012-12-25
Last updated
2020-06-11

Locations

16 sites across 3 countries: Belgium, France, Netherlands

Source: ClinicalTrials.gov record NCT01756326. Inclusion in this directory is not an endorsement.